Rocket One Inc. Investing Cash Flow
Rocket One Inc. (RKTO) reported Investing Cash Flow of $147.20 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-14
- Rocket One Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $0.00.
- Rocket One Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $147.20K.
- Rocket One Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $0.00.
- Rocket One Inc. net cash provided by (used in) investing activities for the quarter ending 2022-12-31 was -$7.50K.
- Rocket One Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$300.00K.
- Rocket One Inc. net cash provided by (used in) investing activities for fiscal 2022 was $1.16M.
- Rocket One Inc. net cash provided by (used in) investing activities for fiscal 2021 was -$165.35K.
- Rocket One Inc. net cash provided by (used in) investing activities for fiscal 2020 was -$1.84M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 8 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $147.20K 10-Q · filed 2026-08-14 | $147.20K derived: sum of 3 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $147.20K 10-Q · filed 2026-05-15 | $147.20K derived: sum of 2 quarters · filed 2026-05-15 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$300.00K 10-K · filed 2026-03-27 | |||
| 2025-09-30 | -$300.00K 10-Q · filed 2025-11-12 | ||||
| 2022-12-31 | -$7.50K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $2.45K derived: sum of 2 quarters · filed 2024-03-28 | $1.19M derived: sum of 3 quarters · filed 2024-03-28 | $1.16M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $9.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.19M derived: sum of 2 quarters · filed 2023-11-13 | $1.17M 10-Q · filed 2023-11-13 | $1.15M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $1.16M 10-Q · filed 2023-08-11 | $1.14M derived: sum of 3 quarters · filed 2023-08-11 | $562.64K derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | -$25.00K 10-Q · filed 2023-05-15 | -$42.48K derived: sum of 2 quarters · filed 2023-05-15 | -$621.60K derived: sum of 3 quarters · filed 2023-05-15 | -$1.15M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | -$17.48K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$596.60K derived: sum of 2 quarters · filed 2023-03-31 | -$1.12M derived: sum of 3 quarters · filed 2023-03-31 | -$165.35K 10-K · filed 2023-03-31 | |
| 2021-09-30 | -$579.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$1.11M derived: sum of 2 quarters · filed 2022-11-10 | -$147.88K 10-Q · filed 2022-11-10 | -$969.63K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$525.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $431.24K 10-Q · filed 2022-08-12 | -$390.52K derived: sum of 3 quarters · filed 2022-08-12 | $281.09K derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | $957.21K 10-Q · filed 2022-05-12 | $135.45K derived: sum of 2 quarters · filed 2022-05-12 | $807.06K derived: sum of 3 quarters · filed 2022-05-12 | -$890.61K derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$821.76K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$150.15K derived: sum of 2 quarters · filed 2022-03-30 | -$1.85M derived: sum of 3 quarters · filed 2022-03-30 | -$1.84M 10-K · filed 2022-03-30 | |
| 2020-09-30 | $671.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$1.03M derived: sum of 2 quarters · filed 2021-11-10 | -$1.02M 10-Q · filed 2021-11-10 | -$1.04M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | -$1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$1.69M 10-Q · filed 2021-08-11 | -$1.71M derived: sum of 3 quarters · filed 2021-08-11 | -$2.56M derived: sum of 4 quarters · filed 2021-08-11 | |
| 2020-03-31 | $10.17K 10-Q · filed 2021-05-13 | -$14.83K derived: sum of 2 quarters · filed 2021-05-13 | -$864.83K derived: sum of 3 quarters · filed 2021-05-13 | -$874.83K derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | -$25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$875.00K derived: sum of 2 quarters · filed 2021-03-16 | -$885.00K derived: sum of 3 quarters · filed 2021-03-16 | -$895.00K 10-K · filed 2021-03-16 | |
| 2019-09-30 | -$850.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$860.00K derived: sum of 2 quarters · filed 2020-11-10 | -$870.00K 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$20.00K 10-Q · filed 2020-08-13 | |||
| 2019-03-31 | -$10.00K 10-Q · filed 2020-05-13 | ||||
| 2017-12-31 | -$303.68K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |